CUPRINA HOLDINGS CAYMAN-A
CUPRNASDAQ🏆 #3885 by market capUS Equity
$2.99▼ $0.05 (−1.81%)
🌙 After hours$2.99▲ 0.00%Regular close · extended-hours price shown1h—
24h▼ 1.8%
7d▼ 12.7%
14d▼ 17.1%
30d▼ 36.8%
1y▼ 95.8%
🏦Market Cap
$8M
Small Cap
📈Revenue Growth (YoY)
+3.3%
Slowing
📊Gross Margin
-1.3%
Thin
💵FCF Margin
-18423.4%
Thin
⚖️P/S Ratio
205.5x
Expensive
Otter Score
55
Weak
Trading Snapshot
- Day Range
- $2.96 – $3.04
- 52-Week Range
- $1.76 – $76.00
- Volume
- $2.61B
- Avg Volume
- $3.26B
- Shares Outstanding
- 2.7M
- Next Earnings
- Sep 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $49,894
- Last Q Revenue
- $26,790
- P/E Ratio
- -2.1
- P/S Ratio
- 205.5x
- EPS (TTM)
- $-1.83
- Dividend Yield
- 0.00%
Why Investors Own CUPR
- ✓High-growth profile — revenue up +25.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 66% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$49,894▲ +25.9% YoY
Gross Margin (TTM)
66.2%▲ +0.1% YoY
Operating Income (TTM)
$15,118▲ +25.9% YoY
Free Cash Flow (TTM)
$11,027▲ +25.9% YoY
About CUPRINA HOLDINGS CAYMAN-A
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
55/100
Analyst Price Target
ⓘAverage Target
$3.11
▲ +4.2% Upside
High Target$3.69
Low Target$2.33
Based on 26 analysts
